ERBB2 and neoplasm: Although BVAC-K1117 that encompasses more immunogenic epitopes located in the ICD regions than BVAC-K684 and BVAC-K965 induced relatively weak antigen-specific antibody responses, it induced more potent antitumor activity than the other two vaccines in murine CT26/HER2 tumor models.